On 17 February, bluebird bio, Inc. (NASDAQ:BLUE) announced treatment of the first patient in a Phase 1 study of its product candidate bb2121 in patients with relapsed/refractory multiple myeloma. bb2121 is a chimeric antigen receptor T cell (CAR T) therapy targeting B cell maturation antigen (BCMA), and bluebird bio is developing bb2121 in collaboration with Celgene Corporation (NASDAQ: CELG).
bluebird bio, Inc. (NASDAQ:BLUE) belongs to Healthcare sector. Its weekly performance is 2.65%. On last trading day company shares ended up at $51.46. bluebird bio, Inc. (NASDAQ:BLUE) distance from 50-day simple moving average (SMA50) is 3.21%.
Southwestern Energy Company (NYSE:SWN) said that, In conjunction with Southwestern Energy Company’s 2015 Fourth Quarter earnings release, invited to listen to its conference call that will be broadcast live over the Internet on Friday, February 26, 2016, at10:00 a.m. EST with Bill Way, President and Chief Executive Officer of Southwestern Energy Company.
Southwestern Energy Company (NYSE:SWN) shares fell -8.68% in last trading session and ended the day at $6.63. SWN Gross Margin is 74.10% and its return on assets is -16.20%. Southwestern Energy Company (NYSE:SWN) quarterly performance is -32.21%.
Regulus Therapeutics Inc. (NASDAQ:RGLS) announced interim results from one of the company’s ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV). The study was designed to evaluate a shortened, four-week treatment regimen containing a subcutaneous administration of 2 mg/kg of RG-101 at Day 1 and Day 29, in combination with 4 weeks of once/daily approved anti-viral agents Harvoni®, Olysio®, or Daklinza™.
On 23 February, Regulus Therapeutics Inc. (NASDAQ:RGLS) shares fell -7.88% and was closed at $7.01. Regulus Therapeutics Inc. (NASDAQ:RGLS) year to date (YTD) performance is -19.61%.
Westamerica Bancorp. (NASDAQ:WABC) ended the last trading day at $44.42. Company weekly volatility is calculated as 3.67% and price to cash ratio as 3.99. Westamerica Bancorp. (NASDAQ:WABC) showed a weekly performance of -6.13%.
OSI Systems, Inc. (NASDAQ:OSIS) had its target price lowered by equities researchers at Benchmark Co. from $102.00 to $83.00 in a note issued to investors on Thursday,AnalystRatings.Net reports. The firm presently has a “buy” rating on the stock. Benchmark Co.’s price objective would suggest a potential upside of 49.82% from the stock’s previous close.
OSI Systems, Inc. (NASDAQ:OSIS) shares fell -2.00% in last trading session and ended the day at $58.87. OSIS Gross Margin is 33.90% and its return on assets is 4.60%. OSI Systems, Inc. (NASDAQ:OSIS) quarterly performance is -37.32%.